Respiratory Motion Inc. (RMI) was founded with the mission to revolutionize respiratory care through innovative technology. The company's vision is to enhance patient outcomes by providing precise and continuous respiratory monitoring. RMI offers advanced respiratory monitoring and ventilation systems, including their flagship product, the ExSpiron™, which measures and provides quantitative values for vital respiratory parameters such as minute ventilation, tidal volume, and respiratory rate. Their market focus includes hospitals, clinics, and other healthcare facilities requiring accurate respiratory monitoring.

Notable affiliated people include key medical professionals and technologists who have contributed to the development of RMI's products. The company has attracted significant investment from healthcare-focused venture capital firms. Key achievements include FDA approval for their devices and widespread adoption in leading medical institutions. Overall, RMI has made a substantial impact on patient care by providing tools that enable better respiratory management and monitoring, thereby improving clinical outcomes and patient safety.